<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int Soc Sports Nutr</journal-id><journal-id journal-id-type="iso-abbrev">J Int Soc Sports Nutr</journal-id><journal-title-group><journal-title>Journal of the International Society of Sports Nutrition</journal-title></journal-title-group><issn pub-type="epub">1550-2783</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29042830</article-id><article-id pub-id-type="pmc">5629791</article-id><article-id pub-id-type="publisher-id">196</article-id><article-id pub-id-type="doi">10.1186/s12970-017-0196-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Marcus</surname><given-names>Lena</given-names></name><address><email>kinesiology@louisina.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Soileau</surname><given-names>Jason</given-names></name><address><email>Jason.Soileau@pbrc.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Judge</surname><given-names>Lawrence W.</given-names></name><address><email>lwjudge@bsu.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8273-1373</contrib-id><name><surname>Bellar</surname><given-names>David</given-names></name><address><phone>(337) 482-6615</phone><email>dbellar@louisiana.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9831 5270</institution-id><institution-id institution-id-type="GRID">grid.266621.7</institution-id><institution>School of Kinesiology, </institution><institution>University of Louisiana at Lafayette, </institution></institution-wrap>Lafayette, LA 70503 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0662 7451</institution-id><institution-id institution-id-type="GRID">grid.64337.35</institution-id><institution>Pennington Biomedical Research Center, </institution><institution>Louisiana State University, </institution></institution-wrap>Baton Rouge, LA 70808 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2111 9017</institution-id><institution-id institution-id-type="GRID">grid.252754.3</institution-id><institution>School of Kinesiology, </institution><institution>Ball State University, </institution></institution-wrap>Muncie, IN 47306 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9831 5270</institution-id><institution-id institution-id-type="GRID">grid.266621.7</institution-id><institution>School of Kinesiology, </institution><institution>University of Louisiana at Lafayette, </institution></institution-wrap>225 Cajundome Blvd, Lafayette, LA 70506 USA </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>14</volume><elocation-id>39</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Recent studies have suggested that alpha glycerylphosphorylcholine (A-GPC) may be an effective ergogenic aid. The present study was designed to assess the efficacy of two doses of A-GPC in comparison to placebo and caffeine for increasing countermovement jump performance, isometric strength, and psychomotor function.</p></sec><sec><title>Methods</title><p id="Par2">Forty-eight healthy, college aged males volunteered for the present study and underwent baseline assessment of countermovement jump (CMJ), isometric mid thigh pull (IMTP), upper body isometric strength test (UBIST), and psychomotor vigilance (PVT). Following this assessment participants were randomly assigned to groups consisting of 500&#x000a0;mg A-GPC, 250&#x000a0;mg A-GPC, 200&#x000a0;mg Caffeine or Placebo taken daily. Blood samples were collected 1&#x000a0;h and 2&#x000a0;h post initial dose to quantify serum free choline and thyroid stimulating hormone then subjects returned after 7&#x000a0;days of supplementation to repeat CMJ, IMTP, UBIST and PVT.</p></sec><sec><title>Results</title><p id="Par3">No differences were noted between groups for IMTP, UBIST or PVT performance. Serum free choline was found to be elevated in the two A-GPC groups as compared to placebo (132% and 59% respectively). Serum TSH was found to be significantly depressed in the 500&#x000a0;mg A-GPC group compared to other treatments (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.04). Group differences were noted for maximum velocity and maximum mechanical power on the CMJ (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) with the 250&#x000a0;mg A-GPC group demonstrating the greatest improvements in result.</p></sec><sec><title>Conclusions</title><p id="Par4">Based upon this evidence, and previous evidence regarding A-GPC, it should be considered as an emerging ergogenic supplement.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Power</kwd><kwd>Strength</kwd><kwd>Reaction time</kwd></kwd-group><funding-group><award-group><funding-source><institution>ChemiNutra</institution></funding-source><award-id>R4475</award-id><principal-award-recipient><name><surname>Bellar</surname><given-names>David</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par9">Choline has been the subject of much study in conjunction with human performance [<xref ref-type="bibr" rid="CR1">1</xref>]. Most of this work has focused on long duration exercise, as choline depletion was thought to play a possible role in fatigue [<xref ref-type="bibr" rid="CR2">2</xref>]. However, it has been reported that after 4&#x000a0;h of strenuous exercise with either 8.4&#x000a0;g choline citrate (administered prior to and midway through exercise) or placebo there was no effect for either run time to exhaustion or squat tests [<xref ref-type="bibr" rid="CR3">3</xref>]. Additionally, in another study, no benefit was seen an hour post 2.43&#x000a0;g choline bitartrate administration for exercise to exhaustion at 70 or 150% of VO<sub>2</sub> max [<xref ref-type="bibr" rid="CR4">4</xref>]. Based upon the results it seems that if choline could be an effective ergogenic aid for endurance efforts, the exercise would likely need to significantly deplete choline [<xref ref-type="bibr" rid="CR1">1</xref>]. Another issue that many of these studies have in common is the use of choline salts, which have been demonstrated to be less effective at increasing free choline levels as compared to molecules involved in the choline biosynthetic pathway such a Lecithin (a source of phosphotidylcholine) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. This is most likely due to these molecules having a normal function in the synthesis of choline, as opposed to just providing a sources of choline. Another molecule in the choline synthesis pathway is alpha glycerylphosphoryl choline (A-GPC), which similarly was shown to significantly increase plasma free choline levels [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par10">Once ingested, A-GPC is converted to phosphorylcholine and can then serve as a source of choline for acetylcholine (ACh) synthesis [<xref ref-type="bibr" rid="CR8">8</xref>]. A large review of clinical studies on dementia or cerebrovascular disorders suggest favorable results for improved cognitive fucntion with A-GPC compared to control or placebo [<xref ref-type="bibr" rid="CR9">9</xref>]. ACh is not only a neurotransmitter, but also responsible for the action potential that stimulates a muscle to contract and thus a role for augmenting performance associated with intense muscle contraction both for enhanced power and strength has been suggested for A-GPC [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The proposed mechanism would include increased ACh as a result of A-GPC ingestion, leading to a more pronounced signal for contraction that results in increased muscle force production. While this is yet and unproven mechanism two recent studies of nutritional supplements containing 300&#x000a0;mg or 150&#x000a0;mg A-GPC suggested improvements in reaction time and vertical jump power [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. These studies provided these doses of A-GPC as part of a nutritional supplement to 19 recreational, college aged adults. These individuals then rested for 10&#x000a0;min and were tested on reaction time, power and exhaustive exercise.</p><p id="Par11">The most recent study on A-GPC [<xref ref-type="bibr" rid="CR11">11</xref>] examined the effects of 600&#x000a0;mg dose on muscle strength. In a group of 13 college aged men, administration of A-GPC resulted in an increase of 98.8&#x000a0;N during an isometric mid thigh pull assessment. The 600&#x000a0;mg dose in this study was similar to that used in previous research that reported positive performance results [<xref ref-type="bibr" rid="CR10">10</xref>]. One issue with the current research on A-GPC is the variation in doses, with some studies examining 1000&#x000a0;mg [<xref ref-type="bibr" rid="CR7">7</xref>] and other studies examining A-GPC within a nutritional supplement at a dose of 150&#x000a0;mg [<xref ref-type="bibr" rid="CR12">12</xref>] and variation in acute vs chronic administration [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. The majority of studies use doses of around 600&#x000a0;mg in an acute fashion, although the only chronic dosing human performance study [<xref ref-type="bibr" rid="CR11">11</xref>] reported changes in force production. Therefore, it is important to more thoroughly examine the dose &#x02013; response relationship of A-GPC to determine what is the required dose for improved performance. The purpose of the present investigation was to examine the effects of 2 doses of A-GPC in comparison to a placebo and caffeine for measures of human performance and cognitive function.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par12">The present study was a double-blind, four arm investigation. The study procedures were reviewed and approved by the Institutional Review Board at the University of Louisiana at Lafayette and all participants gave written informed consent. Four groups of 12 healthy young men volunteered to participate in the study and were randomly assigned to groups (500&#x000a0;mg A-GPC, 250&#x000a0;mg A-GPC, 200&#x000a0;mg Caffeine or placebo). Flowchart of experimental procedures can be seen in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of Experimental Procedures</p></caption><graphic xlink:href="12970_2017_196_Fig1_HTML" id="MO1"/></fig>
</p><sec id="Sec3"><title>Participants</title><p id="Par13">A total of 48 apparently healthy college aged males volunteered to participant in the current investigation (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The participants (<italic>n</italic>&#x000a0;=&#x000a0;48, height 177.6&#x000a0;&#x000b1;&#x000a0;7.7&#x000a0;cm, weight 84.2&#x000a0;&#x000b1;&#x000a0;14.4, BF% 15.3&#x000a0;&#x000b1;&#x000a0;8.3, VO2 Max 33.8&#x000a0;&#x000b1;&#x000a0;22.5&#x000a0;ml/kg*min) were recruited from the local University and represent a convenience sample of recreationally trained subjects. The group reported regular engagement in exercise to maintain or enhance fitness. Group means did not differ in major characteristics (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.5).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Participant characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Group</th><th>Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td rowspan="4">Height (cm)</td><td>500&#x000a0;mg A-GPC</td><td>176.7&#x000a0;&#x000b1;&#x000a0;8.7</td><td char="." align="char" rowspan="4">0.64</td></tr><tr><td>250&#x000a0;mg A&#x02010;GPC</td><td>176.0&#x000a0;&#x000b1;&#x000a0;6.6</td></tr><tr><td>200&#x000a0;mg Caffeine</td><td>179.7&#x000a0;&#x000b1;&#x000a0;8.5</td></tr><tr><td>Placebo</td><td>178.9&#x000a0;&#x000b1;&#x000a0;7.3</td></tr><tr><td rowspan="4">Weight (kg)</td><td>500&#x000a0;mg A&#x02010;GPC</td><td>83.4&#x000a0;&#x000b1;&#x000a0;14.7</td><td char="." align="char" rowspan="4">0.64</td></tr><tr><td>250&#x000a0;mg A&#x02010;GPC</td><td>80.2&#x000a0;&#x000b1;&#x000a0;8.8</td></tr><tr><td>200&#x000a0;mg Caffeine</td><td>86.0&#x000a0;&#x000b1;&#x000a0;21.2</td></tr><tr><td>Placebo</td><td>87.3&#x000a0;&#x000b1;&#x000a0;10.9</td></tr><tr><td rowspan="4">Body Fat%</td><td>500&#x000a0;mg A&#x02010;GPC</td><td>15.3&#x000a0;&#x000b1;&#x000a0;8.9</td><td char="." align="char" rowspan="4">0.83</td></tr><tr><td>250&#x000a0;mg A&#x02010;GPC</td><td>14.7&#x000a0;&#x000b1;&#x000a0;8.6</td></tr><tr><td>200&#x000a0;mg Caffeine</td><td>13.4&#x000a0;&#x000b1;&#x000a0;9.1</td></tr><tr><td>Placebo</td><td>16.9&#x000a0;&#x000b1;&#x000a0;7.5</td></tr><tr><td rowspan="4">VO2 Max (ml/kg*min)</td><td>500&#x000a0;mg A&#x02010;GPC</td><td>33.1&#x000a0;&#x000b1;&#x000a0;6.3</td><td char="." align="char" rowspan="4">0.51</td></tr><tr><td>250&#x000a0;mg A&#x02010;GPC</td><td>34.9&#x000a0;&#x000b1;&#x000a0;6.2</td></tr><tr><td>200&#x000a0;mg Caffeine</td><td>36.5&#x000a0;&#x000b1;&#x000a0;5.9</td></tr><tr><td>Placebo</td><td>30.6&#x000a0;&#x000b1;&#x000a0;4.1</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec4"><title>Procedures</title><p id="Par14">Participant reported to the lab for the initial visit during the morning hours (0600-0700) after an overnight fast (minimum 8&#x000a0;h), had the experimental procedures explained to them and gave written consent to be part of the study. Afterwards height and weight was measured using a physicians triple beam balance and stadiometer. The participants had an assessment of maximum aerobic capacity via a COSMED CPET system (COSMED, Rome ITL) with integrated electronically braked cycle ergometer and body fat percentage via air displacement plethysmography (Bod Pod Gold Standard System, COSMED Rome, ITL). Following these assessments participants performed 3 baseline trials of a countermovement jump, isometric mid-thigh pull, upper body isometric test and a psychomotor vigilance test. The participants were then assigned to groups and given the first dose of the treatment with 237&#x000a0;ml of cool water (500&#x000a0;mg A-GPC, 250&#x000a0;mg A-GPC, 200&#x000a0;mg caffeine or placebo) and sat quietly in the lab for 120&#x000a0;min post consumption. At 60&#x000a0;min and 120&#x000a0;min post ingestion a blood sample was taken to quantify free choline and thyroid stimulating hormone (TSH). The participants were then given supplements to take for the next 6&#x000a0;days in the morning and were dismissed. On the seventh day the participants returned to the lab fasted having taken their last dose of supplement. The subject then repeated the performance and cognitive measures a second time as outlined above.</p></sec><sec id="Sec5"><title>Supplements</title><p id="Par15">The group treatments consisted of two capsules per day for the 7&#x000a0;days of the study. The rational for the number of days of supplementation was based on earlier research on A-GPC [<xref ref-type="bibr" rid="CR11">11</xref>]. Chemi Nutra (Austin TX) supplied all capsule for the study. The A-GPC capsules (both 500&#x000a0;mg and 250&#x000a0;mg) were supplied with a certificate of analysis from an independent lab, verifying active content through Quantitative nuclear magnetic resonance (NMR). The Caffeine capsule content was verified by an independent lab using high performance liquid chromatography (HPLC). Placebo capsules consisted of microcrystalline cellulose.</p></sec><sec id="Sec6"><title>Isometric testing and force plate counter movement jump</title><p id="Par16">The isometric mid-thigh pull test (IMTP) is a well-validated strength measure [<xref ref-type="bibr" rid="CR14">14</xref>] with reported correlations of 0.5-0.8 with actual competition performance. The test equipment consisted of an AMTI force plate (Advanced Materials Technologies Inc., Watertown MA USA) secured beneath a custom Rouge fitness weightlifting rack (Rogue Fitness Inc., Columbus OH USA). The participants were instructed to stand with the feet shoulder width apart above the force plate. The height of the bar was adjusted so that the participant was in a position where the torso was upright, the knees achieved between 120 and 130 degrees of extension (measured via a goniometer) and the arms were straight while holding the bar. The participants&#x02019; hands were secured to the bar via weightlifting hooks to remove the variance associated with grip strength. The participants were told to &#x0201c;drive straight up&#x0201d; and to pull as hard as they could against the bar until the force began to noticeably decline. The peak force was assessed in triplicate at a sampling rate of 2000&#x000a0;Hz using an AMTI Force Plate. The average of the three trials was used for subsequent analysis of variables of interest.</p><p id="Par17">The upper body isometric test (UBIST) used in this study has previously been reported to be both reliable (ICC =0.9) and valid when examined against a 1 RM bench press (<italic>r</italic>&#x000a0;=&#x000a0;.92) [<xref ref-type="bibr" rid="CR15">15</xref>]. The participants were positioned on three elevated platforms with the chest directly suspended over a load cell anchored into the concrete floor of the lab (iLoad Pro, Loadstar Sensors, Fremont CA USA). The load cell chosen has a capacity of greater than 5000 Newtons and a listed accuracy of 0.25% for the full scale of measurement. The participants were placed in a push-up style position, with the hands at 150% of biacromial width, and the elbows at 90 degrees of extension (measured via a goniometer). A thick, non-elastic strap was run over one shoulder and under the opposite shoulder and connected with metal rings to a chain that was tethered to the load cell. The participants were positioned so that no slack was apparent in the chain prior to initiation of data capture.</p><p id="Par18">The participants were instructed to keep their backs flat, and push with their hands maximally until told to stop by the researcher. Prior to data capture the load cell was tared to ensure the weight of the load cell and apparatus were accounted for. The researcher started data collection and verbally instructed the participant to &#x0201c;push as hard as possible&#x0201d;. The load cell captured data (150&#x000a0;Hz) until force noticeable declined (drop of 50&#x000a0;N). The average of three trials was used for subsequent analysis of variables of interest. For the countermovement jump (CMJ) the participants were asked to perform three maximum effort jumps off an AMTI Force Plate (Advanced Materials Technologies Inc., Watertown MA USA). For this test the participant placed their hands on their hips, to remove the influence of the upper body. Data from the test was analyzed using a software package specific to CMJ analysis (Flo Inc., Westbrook, ME USA). The average of the three trials was used for subsequent analysis of variables of interest. Data from this study suggested high reliability with ICC values of greater than 0.8.</p></sec><sec id="Sec7"><title>Cognitive testing</title><p id="Par19">The Walter Reed palm-held psychomotor vigilance test (PVT) was administered to the participants after resting for at least 10&#x000a0;min in a quiet room. The PVT is a test of simple visual reaction time and was developed at the Walter Reed Army Institute of Research [<xref ref-type="bibr" rid="CR16">16</xref>] and was used to assess mean reaction time over a 5-min time course. The test used random periods of time in which a target stimulus are displayed on the screen of a Palm handheld device. The program was set to display approximately 100 stimuli in the 300-s (5&#x000a0;min) period at randomly spaced intervals. This program computes a mean reaction time to each stimulus, as well as major and minor lapses in attention. This instrument has been used in large scale studies conducted by the military and is extensively represented as a reliable (test-retest &#x0003e;0.8) cognitive measure in the literature [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec8"><title>Serum free Choline and thyroid stimulating hormone</title><p id="Par20">Blood was collected at 60 and 120&#x000a0;min post initial dose from a vein in the antecubital space into serum separator tubes. The blood was allowed to clot at room temperature and then a clinical centrifuge was used to separate the serum, which was aliquoted and stored at &#x02212;35 degrees Celsius. At the conclusion of data collection serum aliquots were thawed and free choline levels were determined via a colorimetric assay (BioVision Inc., Milpitas CA USA) read at 450&#x000a0;nm on a microplate reader (ELx 808, Bioteck Winooski VT USA). Similarly, serum TSH was determined by a commercial ELISA kit (Eagle BioScience, Nashua, NH USA).</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par21">Differences in baseline performance were assessed via ANOVA. Changes from average baseline performance for IMTP and UBIST were assessed by group via ANOVA. Serum free choline and TSH levels were analyzed via repeated measures ANOVA. Changes in CMJ variable were analyzed via ANCOVA with body mass as a covariate. PVT performance on day seven was examined via ANOVA by group. All statistical analyses were performed using a modern statistical software package JMP 12.0 (SAS Institute Inc. Cary NC USA). Statistical significance was set a priori at <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Difference in baseline performances</title><p id="Par22">Results of Anova analysis did not reveal any differences in baseline assessments by group for variables associated with isometric measures or counter movement jumps (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.41).</p></sec><sec id="Sec12"><title>Analysis of isometric measures</title><p id="Par23">IMTP change from pre to post supplementation was examined via ANOVA. A significant treatment effect was revealed via the analysis (F&#x000a0;=&#x000a0;2.27, <italic>p</italic>&#x000a0;=&#x000a0;0.047). Post-hoc comparison revealed that only the Caffeine treatment was significantly different than the placebo (<italic>p</italic>&#x000a0;=&#x000a0;0.036). For the UBIST assessment a treatment effect was not revealed via ANOVA (F&#x000a0;=&#x000a0;0.452, <italic>p</italic>&#x000a0;=&#x000a0;0.743). See Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Changes in isometric measures post-supplementation (M&#x000a0;&#x000b1;&#x000a0;SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>500&#x000a0;mg A-GPC</th><th>250&#x000a0;mg A-GPC</th><th>200&#x000a0;mg Caffeine</th><th>Placebo</th></tr></thead><tbody><tr><td>Baseline<break/>IMTP Peak Force (N)</td><td>3000.01&#x000a0;&#x000b1;&#x000a0;611.09</td><td>2815.49&#x000a0;&#x000b1;&#x000a0;504.51</td><td>3297.14&#x000a0;&#x000b1;&#x000a0;768.43</td><td>3149.82&#x000a0;&#x000b1;&#x000a0;885.04</td></tr><tr><td>Post Supplementation<break/>IMTP Peak Force (N)</td><td>2927.82&#x000a0;&#x000b1;&#x000a0;495.66</td><td>2972.48&#x000a0;&#x000b1;&#x000a0;483.67</td><td>3515.24&#x000a0;&#x000b1;&#x000a0;931.61<sup>*</sup>
</td><td>3024.22&#x000a0;&#x000b1;&#x000a0;571.99</td></tr><tr><td>Baseline<break/>UBIST Peak Force (N)</td><td>632.21&#x000a0;&#x000b1;&#x000a0;192.33</td><td>632.18&#x000a0;&#x000b1;&#x000a0;176.29</td><td>700.07&#x000a0;&#x000b1;&#x000a0;221.09</td><td>576.66&#x000a0;&#x000b1;&#x000a0;259.82</td></tr><tr><td>Post Supplementation<break/>UBIST Peak Force (N)</td><td>651.07&#x000a0;&#x000b1;&#x000a0;189.92</td><td>678.52&#x000a0;&#x000b1;&#x000a0;133.34</td><td>715.82&#x000a0;&#x000b1;&#x000a0;176.78</td><td>591.975&#x000a0;&#x000b1;&#x000a0;268.25</td></tr></tbody></table><table-wrap-foot><p>
<sup>*</sup> indicates significantly different than placebo (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05)</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Analysis of countermovement jump measures</title><p id="Par24">For the present investigation average change (pre,post) in mean (trial 1,2,3) maximum force, maximum velocity, maximum impulse, maximum mechanical power and average force were analyzed via ANCOVA (covaried for body mass). No significant differences were revealed for changes in maximum force, average force or impulse. ANCOVA revealed group differences for maximum velocity (F&#x000a0;=&#x000a0;0.247, <italic>p</italic>&#x000a0;=&#x000a0;0.04) and maximum mechanical power (F&#x000a0;=&#x000a0;2.98, <italic>p</italic>&#x000a0;=&#x000a0;0.02) during the countermovement jumps. See Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Changes in countermovement jump measures post-supplementation (M&#x000a0;&#x000b1;&#x000a0;SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>500&#x000a0;mg A-GPC</th><th>250&#x000a0;mg A-GPC</th><th>200&#x000a0;mg Caffeine</th><th>Placebo</th></tr></thead><tbody><tr><td colspan="5">Maximum Force (N)</td></tr><tr><td>&#x02003;Baseline</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Post Supplmentation</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Change</td><td char="&#x000b1;" align="char">&#x02212;69.89&#x000a0;&#x000b1;&#x000a0;187.35</td><td char="&#x000b1;" align="char">76.57&#x000a0;&#x000b1;&#x000a0;195.11</td><td char="&#x000b1;" align="char">&#x02212;57.30&#x000a0;&#x000b1;&#x000a0;306.93</td><td char="&#x000b1;" align="char">&#x02212;68.14&#x000a0;&#x000b1;&#x000a0;195.54</td></tr><tr><td colspan="5">Average Force (N)</td></tr><tr><td>&#x02003;Baseline</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Post Supplmentation</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Change</td><td char="&#x000b1;" align="char">31.08&#x000a0;&#x000b1;&#x000a0;61.29</td><td char="&#x000b1;" align="char">&#x02212;6.67&#x000a0;&#x000b1;&#x000a0;34.18</td><td char="&#x000b1;" align="char">9.24&#x000a0;&#x000b1;&#x000a0;29.37</td><td char="&#x000b1;" align="char">19.16&#x000a0;&#x000b1;&#x000a0;42.59</td></tr><tr><td colspan="5">Maximum Velocity (m/s)</td></tr><tr><td>&#x02003;Baseline</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Post Supplmentation</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Change</td><td char="&#x000b1;" align="char">&#x02212;0.12&#x000a0;&#x000b1;&#x000a0;0.16</td><td char="&#x000b1;" align="char">0.01&#x000a0;&#x000b1;&#x000a0;0.13</td><td char="&#x000b1;" align="char">0.025&#x000a0;&#x000b1;&#x000a0;0.16</td><td char="&#x000b1;" align="char">0.00&#x000a0;&#x000b1;&#x000a0;0.15</td></tr><tr><td colspan="5">Maximum Mechanical Power (Nm/s)</td></tr><tr><td>&#x02003;Baseline</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Post Supplmentation</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Change</td><td char="&#x000b1;" align="char">&#x02212;143.83&#x000a0;&#x000b1;&#x000a0;344.03</td><td char="&#x000b1;" align="char">151.77&#x000a0;&#x000b1;&#x000a0;300.54<sup>*</sup>
</td><td char="&#x000b1;" align="char">7.39&#x000a0;&#x000b1;&#x000a0;309.38</td><td char="&#x000b1;" align="char">31.29&#x000a0;&#x000b1;&#x000a0;277.29</td></tr><tr><td colspan="5">Impulse (Ns)</td></tr><tr><td>&#x02003;Baseline</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Post Supplmentation</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Change</td><td char="&#x000b1;" align="char">69.57&#x000a0;&#x000b1;&#x000a0;61.29</td><td char="&#x000b1;" align="char">66.98&#x000a0;&#x000b1;&#x000a0;10.91</td><td char="&#x000b1;" align="char">75.48&#x000a0;&#x000b1;&#x000a0;19.22</td><td char="&#x000b1;" align="char">73.78&#x000a0;&#x000b1;&#x000a0;17.36</td></tr></tbody></table><table-wrap-foot><p>
<sup>*</sup> indicates significantly different from 500&#x000a0;mg A-GPC <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Analysis of psychomotor vigilance testing</title><p id="Par25">ANOVA was used to examine mean reaction time (RT), maximum reaction time (max RT), and minor lapses in attention (&#x0003e;300&#x000a0;msec). The analysis did not reveal any significant differences by group (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.5). See Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Day 7 Psychomotor vigilance test results (M&#x000a0;&#x000b1;&#x000a0;SD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>500&#x000a0;mg A-GPC</th><th>250&#x000a0;mg A-GPC</th><th>200&#x000a0;mg Caffeine</th><th>Placebo</th></tr></thead><tbody><tr><td>Mean RT (sec)</td><td>0.330&#x000a0;&#x000b1;&#x000a0;0.059</td><td>0.359&#x000a0;&#x000b1;&#x000a0;0.106</td><td>0.315&#x000a0;&#x000b1;&#x000a0;0.070</td><td>0.326&#x000a0;&#x000b1;&#x000a0;0.070</td></tr><tr><td>Max RT (sec)</td><td>2.376&#x000a0;&#x000b1;&#x000a0;3.235</td><td>1.351&#x000a0;&#x000b1;&#x000a0;1.716</td><td>2.149&#x000a0;&#x000b1;&#x000a0;3.914</td><td>1.982&#x000a0;&#x000b1;&#x000a0;3.150</td></tr><tr><td>Minor lapes (count)</td><td>2.916&#x000a0;&#x000b1;&#x000a0;1.621</td><td>5.000&#x000a0;&#x000b1;&#x000a0;1.507</td><td>2.636&#x000a0;&#x000b1;&#x000a0;2.292</td><td>3.833&#x000a0;&#x000b1;&#x000a0;5.937</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec15"><title>Serum free Choline and TSH</title><p id="Par26">Analysis of serum free choline via repeated measures ANOVA resulted in a significant difference by treatment (F&#x000a0;=&#x000a0;14.98 <italic>p</italic>&#x000a0;=&#x000a0;0.001) but not for a treatment by time (1&#x000a0;h, 2&#x000a0;h) interaction (F&#x000a0;=&#x000a0;0.196, <italic>p</italic>&#x000a0;=&#x000a0;0.928). The caffeine and placebo treatment had the lowest free choline levels respectively, with the 250&#x000a0;mg A-GPC and 500&#x000a0;mg A-GPC demonstrating significantly higher levels (132% and 59% respectively).</p><p id="Par27">Analysis of TSH revealed a significant main effect by group. Post hoc analysis revealed significantly lower TSH levels (500&#x000a0;mg of A-GPC 2.29&#x000a0;&#x000b1;&#x000a0;0.51&#x003bc;IU/ml, 3.17&#x000a0;&#x000b1;&#x000a0;1.6 &#x003bc;IU/ml for placebo, 2.97&#x000a0;&#x000b1;&#x000a0;1.03 &#x003bc;IU/ml for 250&#x000a0;mg of A-GPC and 3.08&#x000a0;&#x000b1;&#x000a0;0.83 &#x003bc;IU/ml for Caffeine) with the 500&#x000a0;mg A-GPC dose as compared to all other treatment (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.04).</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par28">The present investigation demonstrated a role for A-GPC in improving power during countermovement jumps and for increasing serum free choline levels. However, these findings require further verification. There have been other studies in the past that have demonstrated increased power [<xref ref-type="bibr" rid="CR10">10</xref>] and isometric strength [<xref ref-type="bibr" rid="CR11">11</xref>] with A-GPC supplementation. However, a recent study [<xref ref-type="bibr" rid="CR17">17</xref>] with a similar design that compared two doses of A-GPC with placebo and caffeine did not demonstrate any significant increases in performance. This study, however, used smaller doses of A-GPC (200&#x000a0;mg, 400&#x000a0;mg) administered acutely 30&#x000a0;min before the performance assessments and additionally did not use forceplate based performance assessments. The data from the present study suggests that 250&#x000a0;mg may represent the minimum dose necessary to see performance changes, however there were great variations in performance amongst the groups. Other studies demonstrating positive results have used doses of 600&#x000a0;mg [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]; therefore this may be the preferred dose at the present with the data available in the literature.</p><p id="Par29">The study also demonstrated that both 250&#x000a0;mg and 500&#x000a0;mg doses of A-GPC were effective at increasing serum free choline, similar to findings reported in an earlier study [<xref ref-type="bibr" rid="CR7">7</xref>] at a dose of 1000&#x000a0;mg. However, the present study did not demonstrate any changes in psychomotor vigilance performance. Though A-GPC has been shown to improve cognitive function in with persons suffering from vascular dementia [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] these studies have generally used much larger doses of A-GPC (1000-1200&#x000a0;mg daily). Additionally, it is more likely that a study would demonstrate change in cognition with a cognitively compromised population as compared to healthy young adults. Therefore, both the study population and the selected doses may have limited detection of changes in psychomotor vigilance.</p><p id="Par30">However the most promising result form this study may be the depression in circulating TSH levels with 500&#x000a0;mg administration of A-GPC. It is known that increase central dopamine levels reduce TSH levels [<xref ref-type="bibr" rid="CR18">18</xref>]. A study by Scanlon et al. [<xref ref-type="bibr" rid="CR18">18</xref>] demonstrated this link through administration of dopamine receptor blockade that lead to significant increases in circulating TSH hormone. Additionally, it has been shown that dopamine infusion inhibits TSH response [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In the present study all subjects given the 500&#x000a0;mg dose were found to have TSH levels below 3.0 &#x003bc;IU/ml with the average being 2.29. In a recent publication these subclinical levels were associated with elevated cortisol, a sign of hypothyroidism [<xref ref-type="bibr" rid="CR21">21</xref>]. This low level of TSH, associated with hypothyroidism, further suggests that the 500&#x000a0;mg dose resulted in a true depression in circulating TSH, possibly caused by increase dopamine. While further exploration of the role of A-GPC in enhancing dopamine is needed to confirm and expand these findings, it suggests a new and exciting area of research. Studies should be conducted in the future to evaluate the potential of A-GPC to enhance dopamine and also cognitive areas such as mood and memory that are effected by dopamine levels.</p></sec><sec id="Sec17"><title>Conclusions</title><p id="Par31">Based upon the available evidence from this study, it appears that A-GPC may maintain some ergogenic effects in doses of 250&#x000a0;mg or greater, although lower doses have been found in other studies to offer various degrees of ergogenic effects [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. It can be suggested that athletes and coaches looking to improve performance in events that emphasize velocity and power consider adding A-GPC to their nutritional strategy; however, based upon the total available literature dose of 600&#x000a0;mg or greater are more likely to provide performance results. While more evidence needs to be collected regarding the use of A-GPC, current results are positive particularly in the area of vertical or countermovement jump where a number of studies have been focused. Future research on A-GPC should focus on larger doses for significant performance benefits, while doses lower than this should focus perhaps on other neurological benefits.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>A-GPC</term><def><p id="Par5">Alpha glycerylphosphrylcholine</p></def></def-item><def-item><term>IMTP</term><def><p id="Par6">Isometric Mid Thigh Pull</p></def></def-item><def-item><term>TSH</term><def><p id="Par7">Thyroid Stimulating Hormone</p></def></def-item><def-item><term>UBIST</term><def><p id="Par8">Upper Body Isometric Test</p></def></def-item></def-list></glossary><ack><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par32">The present study was partially funded by a research grant from Chemi Nutra, Austin TX.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par33">Data are presented in the manuscript, further information available upon request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>LM &#x02013; data collection, data analysis, manuscript development. JS &#x02013; data collection, manuscript development. LWJ - data analysis, manuscript development. DB &#x02013; data collection, data analysis manuscript development. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par34">The present study was reviewed and approved by the Institutional Review Board at the University of Louisiana at Lafayette. All participants gave written informed consent prior to being enrolled in the study.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par35">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par36">The authors declare that they have no competing interests. No person employed by or affiliated with Chemi Nutra had any role in the design of the study, interpretation of the data or development of the manuscript.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par37">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penry</surname><given-names>JT</given-names></name><name><surname>Manore</surname><given-names>MM</given-names></name></person-group><article-title>Choline: an important micronutrient for maximal endurance-exercise performance?</article-title><source>Int J Sport Nutr Exerc Metab</source><year>2008</year><volume>18</volume><issue>2</issue><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1123/ijsnem.18.2.191</pub-id><pub-id pub-id-type="pmid">18458362</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlay</surname><given-names>LA</given-names></name><name><surname>Sabounjian</surname><given-names>LA</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name></person-group><article-title>Exercise and neuromodulators: choline and acetylcholine in marathon runners</article-title><source>Int J Sports Med</source><year>1992</year><volume>13</volume><issue>Suppl 1</issue><fpage>141</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1024619</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warber</surname><given-names>JP</given-names></name><name><surname>Patton</surname><given-names>JF</given-names></name><name><surname>Tharion</surname><given-names>WJ</given-names></name><name><surname>Zeisel</surname><given-names>SH</given-names></name><name><surname>Mello</surname><given-names>RP</given-names></name><name><surname>Kemnitz</surname><given-names>CP</given-names></name><name><surname>Lieberman</surname><given-names>HR</given-names></name></person-group><article-title>The effects of choline supplementation on physical performance</article-title><source>Int J Sport Nutr Exerc Metab</source><year>2000</year><volume>10</volume><issue>2</issue><fpage>170</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1123/ijsnem.10.2.170</pub-id><pub-id pub-id-type="pmid">10861337</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spector</surname><given-names>SA</given-names></name><name><surname>Jackman</surname><given-names>MR</given-names></name><name><surname>Sabounjian</surname><given-names>LA</given-names></name><name><surname>Sakkas</surname><given-names>C</given-names></name><name><surname>Landers</surname><given-names>DM</given-names></name><name><surname>Willis</surname><given-names>WT</given-names></name></person-group><article-title>Effect of choline supplementation on fatigue in trained cyclists</article-title><source>Med Sci Sports Exerc</source><year>1995</year><volume>27</volume><issue>5</issue><fpage>668</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1249/00005768-199505000-00008</pub-id><pub-id pub-id-type="pmid">7674870</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurtman</surname><given-names>MJ</given-names></name><name><surname>Hirsch</surname><given-names>MJ</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name></person-group><article-title>Lecithin consumption raises serum free choline levels</article-title><source>Lancet</source><year>1977</year><volume>2</volume><fpage>68</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(77)90067-8</pub-id><pub-id pub-id-type="pmid">69151</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>MJ</given-names></name><name><surname>Growdon</surname><given-names>JH</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name></person-group><article-title>Relations between dietary choline or lecithin intake, serum choline levels and various metabolic indices</article-title><source>Metabolism</source><year>1978</year><volume>27</volume><fpage>953</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/0026-0495(78)90139-7</pub-id><pub-id pub-id-type="pmid">672614</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Okubo</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Hamaoka</surname><given-names>T</given-names></name><name><surname>Iemitsu</surname><given-names>M</given-names></name></person-group><article-title>Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults</article-title><source>Nutrition</source><year>2012</year><volume>28</volume><fpage>1122</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2012.02.011</pub-id><pub-id pub-id-type="pmid">22673596</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Mignini</surname><given-names>F</given-names></name><name><surname>Tomassoni</surname><given-names>D</given-names></name><name><surname>Traini</surname><given-names>E</given-names></name><name><surname>Amenta</surname><given-names>F</given-names></name></person-group><article-title>Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need to re-evaluate?</article-title><source>J Neurol Sci</source><year>2007</year><volume>257</volume><fpage>264</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2007.01.043</pub-id><pub-id pub-id-type="pmid">17331541</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Amenta</surname><given-names>F</given-names></name><name><surname>Gallai</surname><given-names>V</given-names></name></person-group><article-title>Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data</article-title><source>Mech Ageing Dev</source><year>2001</year><volume>122</volume><fpage>2041</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(01)00312-8</pub-id><pub-id pub-id-type="pmid">11589921</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeigenfuss</surname><given-names>T</given-names></name><name><surname>Landis</surname><given-names>J</given-names></name><name><surname>Hofheins</surname><given-names>J</given-names></name></person-group><article-title>Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise</article-title><source>J Int Soc Sports Nutr</source><year>2008</year><volume>5</volume><issue>Suppl 1</issue><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/1550-2783-5-S1-P15</pub-id><pub-id pub-id-type="pmid">18831752</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellar</surname><given-names>D</given-names></name><name><surname>LeBlanc</surname><given-names>NR</given-names></name><name><surname>Campbell</surname><given-names>B</given-names></name></person-group><article-title>The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength</article-title><source>J Int Soc Sports Nutr</source><year>2015</year><volume>12</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s12970-015-0103-x</pub-id><pub-id pub-id-type="pmid">26582972</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>JR</given-names></name><name><surname>Ratamess</surname><given-names>NA</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Beller</surname><given-names>NA</given-names></name><name><surname>Hoffman</surname><given-names>MW</given-names></name><name><surname>Olxon</surname><given-names>M</given-names></name><name><surname>Purpura</surname><given-names>M</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>R</given-names></name></person-group><article-title>The effects of acute and prolonged CRAM supplementation on reaction time and subjective measures of focus and alertness in healthy college students</article-title><source>J Int Soc Sports Nutr</source><year>2010</year><volume>7</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/1550-2783-7-39</pub-id><pub-id pub-id-type="pmid">21156078</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>KA</given-names></name><name><surname>Silva</surname><given-names>JE</given-names></name><name><surname>Rauch</surname><given-names>JT</given-names></name><name><surname>Lowery</surname><given-names>RP</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>JM</given-names></name></person-group><article-title>The effects of a multi-ingredient cognitive formula on alertness, focus, motivation, calmness, and psychomotor performance in comparison to caffeine and a placebo</article-title><source>J Int Soc Sports Nutr</source><year>2014</year><volume>11</volume><issue>Suppl 1</issue><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/1550-2783-11-S1-P45</pub-id><pub-id pub-id-type="pmid">25302056</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckham</surname><given-names>G</given-names></name><name><surname>Mizuguchi</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Ramsey</surname><given-names>M</given-names></name><name><surname>Lamont</surname><given-names>H</given-names></name><name><surname>Horsby</surname><given-names>G</given-names></name><name><surname>Haff</surname><given-names>G</given-names></name><name><surname>Stone</surname><given-names>M</given-names></name></person-group><article-title>Relationship of isometric mid-thigh pull variables to weighlifting performance</article-title><source>J Sports Med Phys Fitness</source><year>2010</year><volume>35</volume><fpage>573</fpage><lpage>581</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellar</surname><given-names>D</given-names></name><name><surname>Marcus</surname><given-names>L</given-names></name><name><surname>Judge</surname><given-names>LW</given-names></name></person-group><article-title>Validation and reliability of a novel test of upper body isometric strength</article-title><source>J Hum Kinet</source><year>2015</year><volume>47</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1515/hukin-2015-0074</pub-id><pub-id pub-id-type="pmid">26557203</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorne</surname><given-names>DR</given-names></name><name><surname>Johnson</surname><given-names>DE</given-names></name><name><surname>Redmond</surname><given-names>DP</given-names></name><name><surname>Sing</surname><given-names>HC</given-names></name><name><surname>Belenky</surname><given-names>G</given-names></name><name><surname>Shapiro</surname><given-names>JM</given-names></name></person-group><article-title>The Walter Reed palm-held psychomotor vigilance test</article-title><source>Behav Res Methods</source><year>2005</year><volume>37</volume><issue>1</issue><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.3758/BF03206404</pub-id><pub-id pub-id-type="pmid">16097350</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>AG</given-names></name><name><surname>Byars</surname><given-names>A</given-names></name><name><surname>Purpura</surname><given-names>M</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>R</given-names></name></person-group><article-title>The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on makers of mood, cognitive function, power, speed and agility</article-title><source>J Int Soc Sports Nutr</source><year>2015</year><volume>12</volume><issue>Suppl 1</issue><fpage>P41</fpage><pub-id pub-id-type="doi">10.1186/1550-2783-12-S1-P41</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scanlon</surname><given-names>MF</given-names></name><name><surname>Weightman</surname><given-names>DR</given-names></name><name><surname>Shale</surname><given-names>DJ</given-names></name><name><surname>Mora</surname><given-names>B</given-names></name><name><surname>Heath</surname><given-names>M</given-names></name><name><surname>Snow</surname><given-names>MH</given-names></name><name><surname>Lewis</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>R</given-names></name></person-group><article-title>Dopamine is a physiological regulator of thyrotrophin (TSH) secretion</article-title><source>Clin Endocrinol</source><year>1979</year><volume>10</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.1979.tb03028.x</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besses</surname><given-names>GS</given-names></name><name><surname>Burrow</surname><given-names>GN</given-names></name><name><surname>Spaulding</surname><given-names>SW</given-names></name><name><surname>Donabendian</surname><given-names>RK</given-names></name><name><surname>Pechinski</surname><given-names>T</given-names></name></person-group><article-title>Dopamine infusion acutely inhibits the TSH and prolactin response to TRH</article-title><source>J Clin Endo Metab</source><year>1975</year><volume>5</volume><issue>1</issue><fpage>985</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1210/jcem-41-5-985</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>DS</given-names></name><name><surname>Klibanski</surname><given-names>A</given-names></name><name><surname>Ridgway</surname><given-names>EC</given-names></name></person-group><article-title>Dopaminergic modulation of TSH and its subunits: in vivo an in vitro studies</article-title><source>Clin Endo</source><year>1983</year><volume>18</volume><issue>3</issue><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.1983.tb03211.x</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>KN</given-names></name><name><surname>Corwin</surname><given-names>EJ</given-names></name><name><surname>Ulbrecht</surname><given-names>J</given-names></name><name><surname>Demers</surname><given-names>LM</given-names></name><name><surname>Bennett</surname><given-names>JM</given-names></name><name><surname>Whetzel</surname><given-names>CA</given-names></name><name><surname>Klein</surname><given-names>LC</given-names></name></person-group><article-title>Elevated thyroid stimulating hormone is associated with elevated cortisol in healthy young men and women</article-title><source>Thyroid Res</source><year>2012</year><volume>5</volume><issue>1</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/1756-6614-5-13</pub-id><pub-id pub-id-type="pmid">23111240</pub-id></element-citation></ref></ref-list></back></article>